LDLR
Low-density lipoprotein receptor
The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and LDL receptor-related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka megalin), LRP4, and LRP5/6, and LRP8 (aka ApoER2). LDLR family members constitute a class of closely related multifunctional, transmembrane receptors, with diverse functions, from embryonic development to cancer, lipid metabolism, and cardiovascular homeostasis.
All Product Categories
-
LDLR Related Products (89)
Related Products (89)
-
Antibodies (4)
-
R-IMPP hydrochloride
0 ImagesCat. No.: HY-101354ACAS No.: 2173005-10-0Synonyms: PF-00932239 hydrochlorideR-IMPP hydrochloride (PF-00932239 hydrochloride) is a PCSK9 translation inhibitor and a selective 80S ribosome binder. R-IMPP hydrochloride inhibits the KRAS/MEK/ERK signaling cascade. R-IMPP hydrochloride reduces LPS-induced nuclear translocation of NFkB P65. R-IMPP hydrochloride increases LDL-R levels in cells, promotes LDL-C uptake, and does not alter the secretion of transferrin or albumin. R-IMPP hydrochloride inhibits the growth of colorectal cancer (CRC) cells, organoids and xenografts carrying APC/KRAS mutations, as well as the number and burden of spontaneous mouse tumors. R-IMPP hydrochloride can be used in research related to colorectal cancer with APC/KRAS mutations, hepatic ischemia-reperfusion injury and hypercholesterolemia.
-
Pirozadil (Standard)
0 ImagesCat. No.: HY-100144RCAS No.: 54110-25-7Pirozadil (Standard) is the analytical standard of Pirozadil. This product is intended for research and analytical applications. Pirozadil is a hypolipidemic agent.
-
1,2-Cyclohexanedione (Standard)
0 ImagesCat. No.: HY-W007347RCAS No.: 765-87-71,2-Cyclohexanedione is an endogenous metabolite.
-
Obicetrapib hemicalcium
0 ImagesCat. No.: HY-18778CCAS No.: 866399-89-5Synonyms: TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalciumObicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia.
-
Moxonidine-d3
0 ImagesCat. No.: HY-B0374S2Synonyms: BDF5895-d3Moxonidine-d3 (BDF5895-d3) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.
-
Imanixil (Standard)
0 ImagesCat. No.: HY-101529RCAS No.: 75689-93-9Synonyms: HOE-402free base (Standard)Imanixil (Standard) is the analytical standard of Imanixil (HY-101529). This product is intended for research and analytical applications. Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis.
-
Nicanartine
0 ImagesNicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL).
-
Rebaudioside A (Standard)
0 ImagesCat. No.: HY-N0466RCAS No.: 58543-16-1Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
